nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—malignant glioma	0.317	0.463	CbGaD
Mesalazine—PTGS1—malignant glioma	0.234	0.342	CbGaD
Mesalazine—PTGS2—malignant glioma	0.134	0.195	CbGaD
Mesalazine—Lung fibrosis interstitial—Carmustine—malignant glioma	0.00647	0.0518	CcSEcCtD
Mesalazine—Alveolitis—Temozolomide—malignant glioma	0.00575	0.046	CcSEcCtD
Mesalazine—Condition aggravated—Temozolomide—malignant glioma	0.00395	0.0316	CcSEcCtD
Mesalazine—Pneumonia aspiration—Carmustine—malignant glioma	0.00342	0.0273	CcSEcCtD
Mesalazine—Infertility—Carmustine—malignant glioma	0.00286	0.0229	CcSEcCtD
Mesalazine—Infertility—Temozolomide—malignant glioma	0.00276	0.0221	CcSEcCtD
Mesalazine—MPO—endothelium—malignant glioma	0.00243	0.0765	CbGeAlD
Mesalazine—Nephrotoxicity—Carmustine—malignant glioma	0.00235	0.0188	CcSEcCtD
Mesalazine—MPO—blood vessel—malignant glioma	0.00224	0.0705	CbGeAlD
Mesalazine—PPARG—endothelium—malignant glioma	0.00216	0.0679	CbGeAlD
Mesalazine—Skin necrosis—Carmustine—malignant glioma	0.00213	0.0171	CcSEcCtD
Mesalazine—PPARG—blood vessel—malignant glioma	0.00199	0.0626	CbGeAlD
Mesalazine—IKBKB—embryo—malignant glioma	0.00191	0.06	CbGeAlD
Mesalazine—Lung infiltration—Carmustine—malignant glioma	0.00159	0.0127	CcSEcCtD
Mesalazine—IKBKB—telencephalon—malignant glioma	0.00155	0.0488	CbGeAlD
Mesalazine—Tongue discolouration—Temozolomide—malignant glioma	0.00149	0.0119	CcSEcCtD
Mesalazine—Interstitial pneumonia—Temozolomide—malignant glioma	0.00149	0.0119	CcSEcCtD
Mesalazine—Faecal incontinence—Carmustine—malignant glioma	0.00148	0.0118	CcSEcCtD
Mesalazine—Faecal incontinence—Temozolomide—malignant glioma	0.00143	0.0114	CcSEcCtD
Mesalazine—Olsalazine—IFNG—malignant glioma	0.00132	0.231	CrCbGaD
Mesalazine—Nephropathy toxic—Carmustine—malignant glioma	0.0013	0.0104	CcSEcCtD
Mesalazine—CHUK—cerebellum—malignant glioma	0.00127	0.0399	CbGeAlD
Mesalazine—Transaminases increased—Carmustine—malignant glioma	0.00123	0.00981	CcSEcCtD
Mesalazine—Haemorrhoids—Temozolomide—malignant glioma	0.00123	0.00981	CcSEcCtD
Mesalazine—PPARG—embryo—malignant glioma	0.00119	0.0373	CbGeAlD
Mesalazine—Oral candidiasis—Carmustine—malignant glioma	0.00117	0.0094	CcSEcCtD
Mesalazine—PTGS1—endothelium—malignant glioma	0.00115	0.0363	CbGeAlD
Mesalazine—Oral candidiasis—Temozolomide—malignant glioma	0.00113	0.00908	CcSEcCtD
Mesalazine—Parosmia—Temozolomide—malignant glioma	0.00111	0.00889	CcSEcCtD
Mesalazine—PTGS2—endothelium—malignant glioma	0.0011	0.0347	CbGeAlD
Mesalazine—Burning sensation—Carmustine—malignant glioma	0.00107	0.00859	CcSEcCtD
Mesalazine—PTGS1—blood vessel—malignant glioma	0.00106	0.0335	CbGeAlD
Mesalazine—Interstitial lung disease—Carmustine—malignant glioma	0.00105	0.00843	CcSEcCtD
Mesalazine—Thrombosis—Carmustine—malignant glioma	0.00105	0.00843	CcSEcCtD
Mesalazine—CHUK—brain—malignant glioma	0.00103	0.0324	CbGeAlD
Mesalazine—Lung disorder—Temozolomide—malignant glioma	0.00102	0.00815	CcSEcCtD
Mesalazine—Interstitial lung disease—Temozolomide—malignant glioma	0.00102	0.00815	CcSEcCtD
Mesalazine—PTGS2—blood vessel—malignant glioma	0.00102	0.032	CbGeAlD
Mesalazine—Scotoma—Carmustine—malignant glioma	0.000982	0.00786	CcSEcCtD
Mesalazine—Menorrhagia—Temozolomide—malignant glioma	0.000974	0.00779	CcSEcCtD
Mesalazine—Hepatotoxicity—Carmustine—malignant glioma	0.000966	0.00773	CcSEcCtD
Mesalazine—Cholestasis—Temozolomide—malignant glioma	0.000949	0.0076	CcSEcCtD
Mesalazine—Scotoma—Temozolomide—malignant glioma	0.000949	0.0076	CcSEcCtD
Mesalazine—Hepatotoxicity—Temozolomide—malignant glioma	0.000933	0.00747	CcSEcCtD
Mesalazine—Hyperaesthesia—Temozolomide—malignant glioma	0.000918	0.00735	CcSEcCtD
Mesalazine—IKBKB—central nervous system—malignant glioma	0.000882	0.0277	CbGeAlD
Mesalazine—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.000876	0.00701	CcSEcCtD
Mesalazine—IKBKB—cerebellum—malignant glioma	0.000862	0.0271	CbGeAlD
Mesalazine—Liver injury—Temozolomide—malignant glioma	0.000856	0.00686	CcSEcCtD
Mesalazine—Breast pain—Temozolomide—malignant glioma	0.000826	0.00661	CcSEcCtD
Mesalazine—Amenorrhoea—Temozolomide—malignant glioma	0.00082	0.00657	CcSEcCtD
Mesalazine—Leukocytosis—Carmustine—malignant glioma	0.000794	0.00635	CcSEcCtD
Mesalazine—MPO—spinal cord—malignant glioma	0.000763	0.024	CbGeAlD
Mesalazine—Hepatic enzyme increased—Temozolomide—malignant glioma	0.000762	0.0061	CcSEcCtD
Mesalazine—Neck pain—Carmustine—malignant glioma	0.000755	0.00604	CcSEcCtD
Mesalazine—ALOX5—central nervous system—malignant glioma	0.000731	0.023	CbGeAlD
Mesalazine—Musculoskeletal pain—Temozolomide—malignant glioma	0.000729	0.00584	CcSEcCtD
Mesalazine—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.000721	0.00577	CcSEcCtD
Mesalazine—Vaginal inflammation—Temozolomide—malignant glioma	0.000721	0.00577	CcSEcCtD
Mesalazine—ALOX5—cerebellum—malignant glioma	0.000715	0.0225	CbGeAlD
Mesalazine—Candida infection—Carmustine—malignant glioma	0.000712	0.0057	CcSEcCtD
Mesalazine—Skin exfoliation—Carmustine—malignant glioma	0.000712	0.0057	CcSEcCtD
Mesalazine—IKBKB—brain—malignant glioma	0.000701	0.022	CbGeAlD
Mesalazine—Neuropathy—Carmustine—malignant glioma	0.0007	0.0056	CcSEcCtD
Mesalazine—Influenza like illness—Temozolomide—malignant glioma	0.0007	0.0056	CcSEcCtD
Mesalazine—Candida infection—Temozolomide—malignant glioma	0.000688	0.00551	CcSEcCtD
Mesalazine—Skin exfoliation—Temozolomide—malignant glioma	0.000688	0.00551	CcSEcCtD
Mesalazine—Coma—Carmustine—malignant glioma	0.000681	0.00545	CcSEcCtD
Mesalazine—Vaginal infection—Temozolomide—malignant glioma	0.00068	0.00545	CcSEcCtD
Mesalazine—Neuropathy—Temozolomide—malignant glioma	0.000677	0.00542	CcSEcCtD
Mesalazine—Aplastic anaemia—Temozolomide—malignant glioma	0.000677	0.00542	CcSEcCtD
Mesalazine—Salicylate-sodium—PTGS1—malignant glioma	0.000672	0.117	CrCbGaD
Mesalazine—Dry eye—Temozolomide—malignant glioma	0.000666	0.00533	CcSEcCtD
Mesalazine—Olsalazine—PPARG—malignant glioma	0.000624	0.109	CrCbGaD
Mesalazine—MPO—central nervous system—malignant glioma	0.000619	0.0194	CbGeAlD
Mesalazine—Ear pain—Temozolomide—malignant glioma	0.000613	0.00491	CcSEcCtD
Mesalazine—PTGS2—embryo—malignant glioma	0.000607	0.0191	CbGeAlD
Mesalazine—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000601	0.00481	CcSEcCtD
Mesalazine—Eye pain—Carmustine—malignant glioma	0.0006	0.0048	CcSEcCtD
Mesalazine—Gastroenteritis—Temozolomide—malignant glioma	0.00059	0.00472	CcSEcCtD
Mesalazine—Deafness—Temozolomide—malignant glioma	0.000585	0.00468	CcSEcCtD
Mesalazine—Hepatic failure—Temozolomide—malignant glioma	0.000582	0.00466	CcSEcCtD
Mesalazine—ALOX5—brain—malignant glioma	0.000581	0.0182	CbGeAlD
Mesalazine—Eye pain—Temozolomide—malignant glioma	0.000579	0.00464	CcSEcCtD
Mesalazine—Thirst—Temozolomide—malignant glioma	0.00055	0.0044	CcSEcCtD
Mesalazine—PPARG—central nervous system—malignant glioma	0.000549	0.0173	CbGeAlD
Mesalazine—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000541	0.00433	CcSEcCtD
Mesalazine—Face oedema—Carmustine—malignant glioma	0.000523	0.00418	CcSEcCtD
Mesalazine—PTGS1—telencephalon—malignant glioma	0.000516	0.0162	CbGeAlD
Mesalazine—Affect lability—Temozolomide—malignant glioma	0.000515	0.00412	CcSEcCtD
Mesalazine—Face oedema—Temozolomide—malignant glioma	0.000505	0.00404	CcSEcCtD
Mesalazine—Liver function test abnormal—Carmustine—malignant glioma	0.0005	0.004	CcSEcCtD
Mesalazine—Mood swings—Temozolomide—malignant glioma	0.000496	0.00397	CcSEcCtD
Mesalazine—PTGS2—telencephalon—malignant glioma	0.000494	0.0155	CbGeAlD
Mesalazine—MPO—brain—malignant glioma	0.000491	0.0154	CbGeAlD
Mesalazine—Dry skin—Temozolomide—malignant glioma	0.00048	0.00384	CcSEcCtD
Mesalazine—Breast disorder—Temozolomide—malignant glioma	0.000473	0.00378	CcSEcCtD
Mesalazine—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000471	0.00377	CcSEcCtD
Mesalazine—Dysphagia—Carmustine—malignant glioma	0.000468	0.00375	CcSEcCtD
Mesalazine—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000461	0.00369	CcSEcCtD
Mesalazine—Olsalazine—PTGS1—malignant glioma	0.000461	0.0804	CrCbGaD
Mesalazine—Abdominal distension—Temozolomide—malignant glioma	0.000455	0.00364	CcSEcCtD
Mesalazine—Dysphagia—Temozolomide—malignant glioma	0.000452	0.00362	CcSEcCtD
Mesalazine—Pancytopenia—Carmustine—malignant glioma	0.000444	0.00356	CcSEcCtD
Mesalazine—Neutropenia—Carmustine—malignant glioma	0.000438	0.0035	CcSEcCtD
Mesalazine—PPARG—brain—malignant glioma	0.000436	0.0137	CbGeAlD
Mesalazine—Bronchitis—Temozolomide—malignant glioma	0.000435	0.00348	CcSEcCtD
Mesalazine—Aminosalicylic Acid—PTGS1—malignant glioma	0.000433	0.0756	CrCbGaD
Mesalazine—Diflunisal—PTGS1—malignant glioma	0.000433	0.0756	CrCbGaD
Mesalazine—Pancytopenia—Temozolomide—malignant glioma	0.000429	0.00344	CcSEcCtD
Mesalazine—Dysuria—Temozolomide—malignant glioma	0.000423	0.00338	CcSEcCtD
Mesalazine—Neutropenia—Temozolomide—malignant glioma	0.000423	0.00338	CcSEcCtD
Mesalazine—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00042	0.00336	CcSEcCtD
Mesalazine—Pneumonia—Carmustine—malignant glioma	0.00042	0.00336	CcSEcCtD
Mesalazine—Pollakiuria—Temozolomide—malignant glioma	0.000418	0.00334	CcSEcCtD
Mesalazine—Depression—Carmustine—malignant glioma	0.000416	0.00333	CcSEcCtD
Mesalazine—Photosensitivity reaction—Temozolomide—malignant glioma	0.000413	0.0033	CcSEcCtD
Mesalazine—Weight increased—Temozolomide—malignant glioma	0.000411	0.00329	CcSEcCtD
Mesalazine—Renal failure—Carmustine—malignant glioma	0.00041	0.00328	CcSEcCtD
Mesalazine—Weight decreased—Temozolomide—malignant glioma	0.000409	0.00327	CcSEcCtD
Mesalazine—Neuropathy peripheral—Carmustine—malignant glioma	0.000409	0.00327	CcSEcCtD
Mesalazine—Stomatitis—Carmustine—malignant glioma	0.000407	0.00325	CcSEcCtD
Mesalazine—Urinary tract infection—Carmustine—malignant glioma	0.000406	0.00325	CcSEcCtD
Mesalazine—Pneumonia—Temozolomide—malignant glioma	0.000406	0.00325	CcSEcCtD
Mesalazine—Infestation—Temozolomide—malignant glioma	0.000403	0.00323	CcSEcCtD
Mesalazine—Infestation NOS—Temozolomide—malignant glioma	0.000403	0.00323	CcSEcCtD
Mesalazine—Depression—Temozolomide—malignant glioma	0.000402	0.00322	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.0004	0.0032	CcSEcCtD
Mesalazine—Neuropathy peripheral—Temozolomide—malignant glioma	0.000395	0.00316	CcSEcCtD
Mesalazine—Stomatitis—Temozolomide—malignant glioma	0.000393	0.00315	CcSEcCtD
Mesalazine—Urinary tract infection—Temozolomide—malignant glioma	0.000392	0.00314	CcSEcCtD
Mesalazine—PTGS2—medulla oblongata—malignant glioma	0.000388	0.0122	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—malignant glioma	0.000384	0.0671	CrCbGaD
Mesalazine—Hepatobiliary disease—Temozolomide—malignant glioma	0.000381	0.00305	CcSEcCtD
Mesalazine—Sinusitis—Temozolomide—malignant glioma	0.000378	0.00303	CcSEcCtD
Mesalazine—Haemoglobin—Carmustine—malignant glioma	0.000376	0.00301	CcSEcCtD
Mesalazine—Haemorrhage—Carmustine—malignant glioma	0.000375	0.003	CcSEcCtD
Mesalazine—Oedema peripheral—Carmustine—malignant glioma	0.000369	0.00295	CcSEcCtD
Mesalazine—Connective tissue disorder—Carmustine—malignant glioma	0.000368	0.00295	CcSEcCtD
Mesalazine—Haemoglobin—Temozolomide—malignant glioma	0.000364	0.00291	CcSEcCtD
Mesalazine—Hepatitis—Temozolomide—malignant glioma	0.000362	0.0029	CcSEcCtD
Mesalazine—Haemorrhage—Temozolomide—malignant glioma	0.000362	0.0029	CcSEcCtD
Mesalazine—PTGS1—spinal cord—malignant glioma	0.000362	0.0114	CbGeAlD
Mesalazine—Pharyngitis—Temozolomide—malignant glioma	0.000359	0.00288	CcSEcCtD
Mesalazine—Urinary tract disorder—Temozolomide—malignant glioma	0.000357	0.00286	CcSEcCtD
Mesalazine—Oedema peripheral—Temozolomide—malignant glioma	0.000357	0.00285	CcSEcCtD
Mesalazine—Connective tissue disorder—Temozolomide—malignant glioma	0.000356	0.00285	CcSEcCtD
Mesalazine—Urethral disorder—Temozolomide—malignant glioma	0.000355	0.00284	CcSEcCtD
Mesalazine—PTGS2—midbrain—malignant glioma	0.000354	0.0111	CbGeAlD
Mesalazine—Eye disorder—Carmustine—malignant glioma	0.00035	0.0028	CcSEcCtD
Mesalazine—PTGS2—spinal cord—malignant glioma	0.000346	0.0109	CbGeAlD
Mesalazine—Erythema multiforme—Temozolomide—malignant glioma	0.000342	0.00274	CcSEcCtD
Mesalazine—Eye disorder—Temozolomide—malignant glioma	0.000338	0.00271	CcSEcCtD
Mesalazine—Tinnitus—Temozolomide—malignant glioma	0.000337	0.0027	CcSEcCtD
Mesalazine—Cardiac disorder—Temozolomide—malignant glioma	0.000336	0.00269	CcSEcCtD
Mesalazine—Alopecia—Carmustine—malignant glioma	0.000331	0.00265	CcSEcCtD
Mesalazine—Angiopathy—Temozolomide—malignant glioma	0.000328	0.00263	CcSEcCtD
Mesalazine—Mental disorder—Carmustine—malignant glioma	0.000328	0.00263	CcSEcCtD
Mesalazine—Immune system disorder—Temozolomide—malignant glioma	0.000327	0.00262	CcSEcCtD
Mesalazine—Mediastinal disorder—Temozolomide—malignant glioma	0.000326	0.00261	CcSEcCtD
Mesalazine—Erythema—Carmustine—malignant glioma	0.000326	0.00261	CcSEcCtD
Mesalazine—Chills—Temozolomide—malignant glioma	0.000325	0.0026	CcSEcCtD
Mesalazine—Alopecia—Temozolomide—malignant glioma	0.00032	0.00256	CcSEcCtD
Mesalazine—Mental disorder—Temozolomide—malignant glioma	0.000317	0.00254	CcSEcCtD
Mesalazine—Back pain—Carmustine—malignant glioma	0.000315	0.00252	CcSEcCtD
Mesalazine—Erythema—Temozolomide—malignant glioma	0.000315	0.00252	CcSEcCtD
Mesalazine—Dysgeusia—Temozolomide—malignant glioma	0.000309	0.00247	CcSEcCtD
Mesalazine—Vision blurred—Carmustine—malignant glioma	0.000307	0.00246	CcSEcCtD
Mesalazine—Tremor—Carmustine—malignant glioma	0.000305	0.00244	CcSEcCtD
Mesalazine—Back pain—Temozolomide—malignant glioma	0.000305	0.00244	CcSEcCtD
Mesalazine—Anaemia—Carmustine—malignant glioma	0.000301	0.00241	CcSEcCtD
Mesalazine—Vision blurred—Temozolomide—malignant glioma	0.000297	0.00238	CcSEcCtD
Mesalazine—Tremor—Temozolomide—malignant glioma	0.000295	0.00236	CcSEcCtD
Mesalazine—PTGS1—central nervous system—malignant glioma	0.000294	0.00923	CbGeAlD
Mesalazine—Ill-defined disorder—Temozolomide—malignant glioma	0.000292	0.00234	CcSEcCtD
Mesalazine—Leukopenia—Carmustine—malignant glioma	0.000292	0.00234	CcSEcCtD
Mesalazine—Anaemia—Temozolomide—malignant glioma	0.000291	0.00233	CcSEcCtD
Mesalazine—Angioedema—Temozolomide—malignant glioma	0.000288	0.0023	CcSEcCtD
Mesalazine—Malaise—Temozolomide—malignant glioma	0.000284	0.00227	CcSEcCtD
Mesalazine—Vertigo—Temozolomide—malignant glioma	0.000283	0.00227	CcSEcCtD
Mesalazine—Leukopenia—Temozolomide—malignant glioma	0.000282	0.00226	CcSEcCtD
Mesalazine—Hypertension—Carmustine—malignant glioma	0.000281	0.00225	CcSEcCtD
Mesalazine—PTGS2—central nervous system—malignant glioma	0.000281	0.00882	CbGeAlD
Mesalazine—Palpitations—Temozolomide—malignant glioma	0.000278	0.00223	CcSEcCtD
Mesalazine—Myalgia—Carmustine—malignant glioma	0.000278	0.00222	CcSEcCtD
Mesalazine—Chest pain—Carmustine—malignant glioma	0.000278	0.00222	CcSEcCtD
Mesalazine—Anxiety—Carmustine—malignant glioma	0.000277	0.00221	CcSEcCtD
Mesalazine—Cough—Temozolomide—malignant glioma	0.000275	0.0022	CcSEcCtD
Mesalazine—PTGS2—cerebellum—malignant glioma	0.000274	0.00862	CbGeAlD
Mesalazine—Hypertension—Temozolomide—malignant glioma	0.000272	0.00218	CcSEcCtD
Mesalazine—Confusional state—Carmustine—malignant glioma	0.000268	0.00215	CcSEcCtD
Mesalazine—Myalgia—Temozolomide—malignant glioma	0.000268	0.00215	CcSEcCtD
Mesalazine—Arthralgia—Temozolomide—malignant glioma	0.000268	0.00215	CcSEcCtD
Mesalazine—Anxiety—Temozolomide—malignant glioma	0.000267	0.00214	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000266	0.00213	CcSEcCtD
Mesalazine—Oedema—Carmustine—malignant glioma	0.000266	0.00213	CcSEcCtD
Mesalazine—Discomfort—Temozolomide—malignant glioma	0.000265	0.00212	CcSEcCtD
Mesalazine—Infection—Carmustine—malignant glioma	0.000264	0.00212	CcSEcCtD
Mesalazine—Olsalazine—PTGS2—malignant glioma	0.000263	0.046	CrCbGaD
Mesalazine—Dry mouth—Temozolomide—malignant glioma	0.000262	0.0021	CcSEcCtD
Mesalazine—Thrombocytopenia—Carmustine—malignant glioma	0.000261	0.00209	CcSEcCtD
Mesalazine—Dopamine—SLC6A3—malignant glioma	0.00026	0.0453	CrCbGaD
Mesalazine—Tachycardia—Carmustine—malignant glioma	0.00026	0.00208	CcSEcCtD
Mesalazine—Confusional state—Temozolomide—malignant glioma	0.000259	0.00208	CcSEcCtD
Mesalazine—Oedema—Temozolomide—malignant glioma	0.000257	0.00206	CcSEcCtD
Mesalazine—Anaphylactic shock—Temozolomide—malignant glioma	0.000257	0.00206	CcSEcCtD
Mesalazine—Infection—Temozolomide—malignant glioma	0.000255	0.00204	CcSEcCtD
Mesalazine—Anorexia—Carmustine—malignant glioma	0.000254	0.00203	CcSEcCtD
Mesalazine—Nervous system disorder—Temozolomide—malignant glioma	0.000252	0.00202	CcSEcCtD
Mesalazine—Thrombocytopenia—Temozolomide—malignant glioma	0.000252	0.00202	CcSEcCtD
Mesalazine—Skin disorder—Temozolomide—malignant glioma	0.00025	0.002	CcSEcCtD
Mesalazine—Hypotension—Carmustine—malignant glioma	0.000249	0.00199	CcSEcCtD
Mesalazine—Hyperhidrosis—Temozolomide—malignant glioma	0.000249	0.00199	CcSEcCtD
Mesalazine—Diflunisal—PTGS2—malignant glioma	0.000248	0.0432	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—malignant glioma	0.000248	0.0432	CrCbGaD
Mesalazine—Anorexia—Temozolomide—malignant glioma	0.000245	0.00196	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000242	0.00194	CcSEcCtD
Mesalazine—Salicylic acid—PTGS1—malignant glioma	0.000241	0.0421	CrCbGaD
Mesalazine—Insomnia—Carmustine—malignant glioma	0.000241	0.00193	CcSEcCtD
Mesalazine—Paraesthesia—Carmustine—malignant glioma	0.000239	0.00191	CcSEcCtD
Mesalazine—Dyspnoea—Carmustine—malignant glioma	0.000237	0.0019	CcSEcCtD
Mesalazine—Somnolence—Carmustine—malignant glioma	0.000237	0.00189	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000234	0.00188	CcSEcCtD
Mesalazine—PTGS1—brain—malignant glioma	0.000233	0.00732	CbGeAlD
Mesalazine—Insomnia—Temozolomide—malignant glioma	0.000233	0.00186	CcSEcCtD
Mesalazine—Decreased appetite—Carmustine—malignant glioma	0.000231	0.00185	CcSEcCtD
Mesalazine—Paraesthesia—Temozolomide—malignant glioma	0.000231	0.00185	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Carmustine—malignant glioma	0.00023	0.00184	CcSEcCtD
Mesalazine—Dyspnoea—Temozolomide—malignant glioma	0.000229	0.00183	CcSEcCtD
Mesalazine—Somnolence—Temozolomide—malignant glioma	0.000229	0.00183	CcSEcCtD
Mesalazine—Pain—Carmustine—malignant glioma	0.000228	0.00182	CcSEcCtD
Mesalazine—Constipation—Carmustine—malignant glioma	0.000228	0.00182	CcSEcCtD
Mesalazine—Dyspepsia—Temozolomide—malignant glioma	0.000226	0.00181	CcSEcCtD
Mesalazine—Decreased appetite—Temozolomide—malignant glioma	0.000224	0.00179	CcSEcCtD
Mesalazine—PTGS2—brain—malignant glioma	0.000223	0.007	CbGeAlD
Mesalazine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000222	0.00178	CcSEcCtD
Mesalazine—Fatigue—Temozolomide—malignant glioma	0.000222	0.00177	CcSEcCtD
Mesalazine—Constipation—Temozolomide—malignant glioma	0.00022	0.00176	CcSEcCtD
Mesalazine—Pain—Temozolomide—malignant glioma	0.00022	0.00176	CcSEcCtD
Mesalazine—Feeling abnormal—Carmustine—malignant glioma	0.000219	0.00176	CcSEcCtD
Mesalazine—Gastrointestinal pain—Carmustine—malignant glioma	0.000218	0.00174	CcSEcCtD
Mesalazine—Feeling abnormal—Temozolomide—malignant glioma	0.000212	0.0017	CcSEcCtD
Mesalazine—Abdominal pain—Carmustine—malignant glioma	0.00021	0.00168	CcSEcCtD
Mesalazine—Body temperature increased—Carmustine—malignant glioma	0.00021	0.00168	CcSEcCtD
Mesalazine—Gastrointestinal pain—Temozolomide—malignant glioma	0.00021	0.00168	CcSEcCtD
Mesalazine—Urticaria—Temozolomide—malignant glioma	0.000204	0.00164	CcSEcCtD
Mesalazine—Abdominal pain—Temozolomide—malignant glioma	0.000203	0.00163	CcSEcCtD
Mesalazine—Body temperature increased—Temozolomide—malignant glioma	0.000203	0.00163	CcSEcCtD
Mesalazine—Hypersensitivity—Carmustine—malignant glioma	0.000196	0.00157	CcSEcCtD
Mesalazine—Asthenia—Carmustine—malignant glioma	0.000191	0.00153	CcSEcCtD
Mesalazine—Hypersensitivity—Temozolomide—malignant glioma	0.000189	0.00152	CcSEcCtD
Mesalazine—Asthenia—Temozolomide—malignant glioma	0.000184	0.00148	CcSEcCtD
Mesalazine—Diarrhoea—Carmustine—malignant glioma	0.000182	0.00146	CcSEcCtD
Mesalazine—Pruritus—Temozolomide—malignant glioma	0.000182	0.00146	CcSEcCtD
Mesalazine—Dizziness—Carmustine—malignant glioma	0.000176	0.00141	CcSEcCtD
Mesalazine—Diarrhoea—Temozolomide—malignant glioma	0.000176	0.00141	CcSEcCtD
Mesalazine—Dizziness—Temozolomide—malignant glioma	0.00017	0.00136	CcSEcCtD
Mesalazine—Vomiting—Carmustine—malignant glioma	0.000169	0.00135	CcSEcCtD
Mesalazine—Rash—Carmustine—malignant glioma	0.000168	0.00134	CcSEcCtD
Mesalazine—Dermatitis—Carmustine—malignant glioma	0.000168	0.00134	CcSEcCtD
Mesalazine—Headache—Carmustine—malignant glioma	0.000167	0.00133	CcSEcCtD
Mesalazine—Vomiting—Temozolomide—malignant glioma	0.000163	0.00131	CcSEcCtD
Mesalazine—Rash—Temozolomide—malignant glioma	0.000162	0.0013	CcSEcCtD
Mesalazine—Dermatitis—Temozolomide—malignant glioma	0.000162	0.0013	CcSEcCtD
Mesalazine—Headache—Temozolomide—malignant glioma	0.000161	0.00129	CcSEcCtD
Mesalazine—Nausea—Carmustine—malignant glioma	0.000158	0.00127	CcSEcCtD
Mesalazine—Nausea—Temozolomide—malignant glioma	0.000153	0.00122	CcSEcCtD
Mesalazine—Salicylic acid—PTGS2—malignant glioma	0.000138	0.024	CrCbGaD
Mesalazine—PTGS2—Disease—FBXW7—malignant glioma	1.36e-05	8.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—malignant glioma	1.36e-05	8.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGF—malignant glioma	1.35e-05	8.91e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.35e-05	8.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTPN11—malignant glioma	1.35e-05	8.86e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH2—malignant glioma	1.33e-05	8.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTT1—malignant glioma	1.33e-05	8.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—BAD—malignant glioma	1.31e-05	8.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KNG1—malignant glioma	1.3e-05	8.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOTCH1—malignant glioma	1.29e-05	8.51e-05	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	1.29e-05	8.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BAD—malignant glioma	1.28e-05	8.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP3—malignant glioma	1.27e-05	8.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD80—malignant glioma	1.27e-05	8.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—malignant glioma	1.27e-05	8.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—APC—malignant glioma	1.27e-05	8.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN2B—malignant glioma	1.26e-05	8.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT2—malignant glioma	1.25e-05	8.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGF—malignant glioma	1.25e-05	8.23e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD80—malignant glioma	1.24e-05	8.19e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTGS1—malignant glioma	1.24e-05	8.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTPN11—malignant glioma	1.24e-05	8.18e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CAV1—malignant glioma	1.24e-05	8.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.24e-05	8.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NTRK1—malignant glioma	1.24e-05	8.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGF—malignant glioma	1.23e-05	8.08e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTK2—malignant glioma	1.22e-05	8.03e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTPN11—malignant glioma	1.22e-05	8.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—malignant glioma	1.22e-05	8e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—malignant glioma	1.21e-05	7.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CD—malignant glioma	1.2e-05	7.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HES1—malignant glioma	1.2e-05	7.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—malignant glioma	1.2e-05	7.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NCOR1—malignant glioma	1.19e-05	7.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—BRAF—malignant glioma	1.19e-05	7.82e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.18e-05	7.79e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.18e-05	7.73e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTP1—malignant glioma	1.16e-05	7.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT2—malignant glioma	1.16e-05	7.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—BCHE—malignant glioma	1.16e-05	7.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—FGF2—malignant glioma	1.15e-05	7.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP3—malignant glioma	1.15e-05	7.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—malignant glioma	1.15e-05	7.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—malignant glioma	1.15e-05	7.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PDGFRA—malignant glioma	1.14e-05	7.52e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—SLC5A5—malignant glioma	1.14e-05	7.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN2B—malignant glioma	1.14e-05	7.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT2—malignant glioma	1.14e-05	7.48e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CG—malignant glioma	1.13e-05	7.42e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAT—malignant glioma	1.13e-05	7.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CD—malignant glioma	1.11e-05	7.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SPP1—malignant glioma	1.11e-05	7.3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTK2—malignant glioma	1.11e-05	7.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—malignant glioma	1.1e-05	7.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PIK3CA—malignant glioma	1.1e-05	7.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—BCL2—malignant glioma	1.1e-05	7.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CD—malignant glioma	1.09e-05	7.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HES1—malignant glioma	1.09e-05	7.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNG—malignant glioma	1.09e-05	7.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—malignant glioma	1.08e-05	7.13e-05	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—AKT1—malignant glioma	1.08e-05	7.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NCOR1—malignant glioma	1.08e-05	7.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.08e-05	7.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MDM2—malignant glioma	1.08e-05	7.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RAF1—malignant glioma	1.08e-05	7.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—FGF2—malignant glioma	1.06e-05	7e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NCOR1—malignant glioma	1.06e-05	7e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN2B—malignant glioma	1.06e-05	7e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—malignant glioma	1.06e-05	7e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—malignant glioma	1.06e-05	6.94e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—malignant glioma	1.05e-05	6.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CB—malignant glioma	1.05e-05	6.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FGF2—malignant glioma	1.05e-05	6.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—malignant glioma	1.04e-05	6.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDGFRA—malignant glioma	1.04e-05	6.81e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PDGFB—malignant glioma	1.03e-05	6.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGFR1—malignant glioma	1.02e-05	6.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HES1—malignant glioma	1.02e-05	6.68e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NCOR1—malignant glioma	1.01e-05	6.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SPP1—malignant glioma	1.01e-05	6.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—malignant glioma	1.01e-05	6.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—malignant glioma	9.97e-06	6.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MDM2—malignant glioma	9.96e-06	6.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—BCL2—malignant glioma	9.93e-06	6.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—RAF1—malignant glioma	9.93e-06	6.53e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CD—malignant glioma	9.92e-06	6.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—malignant glioma	9.84e-06	6.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—malignant glioma	9.82e-06	6.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MDM2—malignant glioma	9.79e-06	6.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RAF1—malignant glioma	9.75e-06	6.41e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CAV1—malignant glioma	9.73e-06	6.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—malignant glioma	9.69e-06	6.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL1B—malignant glioma	9.68e-06	6.37e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFRA—malignant glioma	9.67e-06	6.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—malignant glioma	9.65e-06	6.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—malignant glioma	9.64e-06	6.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—malignant glioma	9.62e-06	6.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—malignant glioma	9.61e-06	6.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—malignant glioma	9.57e-06	6.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—malignant glioma	9.54e-06	6.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—malignant glioma	9.52e-06	6.26e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	9.33e-06	6.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PDGFB—malignant glioma	9.31e-06	6.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR1—malignant glioma	9.26e-06	6.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—F2—malignant glioma	9.26e-06	6.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FN1—malignant glioma	9.26e-06	6.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—malignant glioma	9.2e-06	6.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BAD—malignant glioma	9.15e-06	6.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—malignant glioma	9.12e-06	6e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—malignant glioma	9.07e-06	5.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NOTCH1—malignant glioma	9.06e-06	5.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—malignant glioma	8.98e-06	5.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAT—malignant glioma	8.95e-06	5.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—malignant glioma	8.9e-06	5.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HLA-A—malignant glioma	8.9e-06	5.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CD80—malignant glioma	8.88e-06	5.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—malignant glioma	8.86e-06	5.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—malignant glioma	8.86e-06	5.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CAV1—malignant glioma	8.82e-06	5.8e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL1B—malignant glioma	8.78e-06	5.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGF—malignant glioma	8.76e-06	5.76e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—malignant glioma	8.74e-06	5.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—malignant glioma	8.72e-06	5.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTPN11—malignant glioma	8.7e-06	5.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PDGFB—malignant glioma	8.68e-06	5.71e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAV1—malignant glioma	8.68e-06	5.71e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—malignant glioma	8.65e-06	5.69e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR1—malignant glioma	8.64e-06	5.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—malignant glioma	8.62e-06	5.67e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—malignant glioma	8.57e-06	5.64e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—malignant glioma	8.52e-06	5.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—malignant glioma	8.51e-06	5.6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NCOR1—malignant glioma	8.45e-06	5.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FN1—malignant glioma	8.39e-06	5.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—F2—malignant glioma	8.39e-06	5.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—malignant glioma	8.38e-06	5.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—malignant glioma	8.33e-06	5.48e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BAD—malignant glioma	8.3e-06	5.46e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	8.29e-06	5.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CAV1—malignant glioma	8.23e-06	5.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—malignant glioma	8.23e-06	5.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NOTCH1—malignant glioma	8.22e-06	5.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—malignant glioma	8.14e-06	5.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—malignant glioma	8.11e-06	5.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT2—malignant glioma	8.11e-06	5.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CD80—malignant glioma	8.05e-06	5.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—malignant glioma	8.03e-06	5.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—malignant glioma	8.03e-06	5.28e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—malignant glioma	7.99e-06	5.25e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGF—malignant glioma	7.94e-06	5.22e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—malignant glioma	7.91e-06	5.2e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTPN11—malignant glioma	7.89e-06	5.19e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—malignant glioma	7.82e-06	5.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—malignant glioma	7.79e-06	5.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BAD—malignant glioma	7.74e-06	5.09e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOTCH1—malignant glioma	7.66e-06	5.04e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—malignant glioma	7.63e-06	5.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—malignant glioma	7.55e-06	4.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD80—malignant glioma	7.51e-06	4.94e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—malignant glioma	7.49e-06	4.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—malignant glioma	7.49e-06	4.93e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—malignant glioma	7.47e-06	4.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGF2—malignant glioma	7.46e-06	4.91e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGF—malignant glioma	7.41e-06	4.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—malignant glioma	7.38e-06	4.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTPN11—malignant glioma	7.36e-06	4.84e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—malignant glioma	7.36e-06	4.84e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT2—malignant glioma	7.35e-06	4.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—malignant glioma	7.06e-06	4.65e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—malignant glioma	7.04e-06	4.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—malignant glioma	6.98e-06	4.59e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—malignant glioma	6.97e-06	4.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—malignant glioma	6.96e-06	4.58e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—malignant glioma	6.96e-06	4.58e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAF1—malignant glioma	6.95e-06	4.57e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—malignant glioma	6.95e-06	4.57e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAV1—malignant glioma	6.89e-06	4.53e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—malignant glioma	6.88e-06	4.52e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT2—malignant glioma	6.86e-06	4.51e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—malignant glioma	6.81e-06	4.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—malignant glioma	6.79e-06	4.47e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGF2—malignant glioma	6.76e-06	4.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—malignant glioma	6.69e-06	4.4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—malignant glioma	6.59e-06	4.33e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.58e-06	4.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—malignant glioma	6.52e-06	4.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—malignant glioma	6.43e-06	4.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—malignant glioma	6.4e-06	4.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—malignant glioma	6.33e-06	4.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—malignant glioma	6.32e-06	4.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGF2—malignant glioma	6.31e-06	4.15e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAF1—malignant glioma	6.31e-06	4.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—malignant glioma	6.28e-06	4.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—malignant glioma	6.24e-06	4.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—malignant glioma	6.24e-06	4.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—malignant glioma	6.23e-06	4.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—malignant glioma	6.16e-06	4.05e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—malignant glioma	6.06e-06	3.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—malignant glioma	6.06e-06	3.98e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—malignant glioma	6e-06	3.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—malignant glioma	5.92e-06	3.89e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—malignant glioma	5.91e-06	3.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—malignant glioma	5.9e-06	3.88e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—malignant glioma	5.9e-06	3.88e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RAF1—malignant glioma	5.88e-06	3.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—malignant glioma	5.87e-06	3.86e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—malignant glioma	5.82e-06	3.83e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—malignant glioma	5.8e-06	3.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—malignant glioma	5.74e-06	3.78e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—malignant glioma	5.66e-06	3.72e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—malignant glioma	5.65e-06	3.72e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—malignant glioma	5.54e-06	3.64e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—malignant glioma	5.52e-06	3.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—malignant glioma	5.35e-06	3.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—malignant glioma	5.32e-06	3.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—malignant glioma	5.3e-06	3.49e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—malignant glioma	5.27e-06	3.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—malignant glioma	5.25e-06	3.45e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—malignant glioma	5.24e-06	3.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—malignant glioma	5.23e-06	3.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—malignant glioma	4.96e-06	3.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—malignant glioma	4.88e-06	3.21e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—malignant glioma	4.83e-06	3.18e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—malignant glioma	4.81e-06	3.16e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—malignant glioma	4.8e-06	3.16e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—malignant glioma	4.77e-06	3.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—malignant glioma	4.76e-06	3.13e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—malignant glioma	4.74e-06	3.12e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—malignant glioma	4.5e-06	2.96e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—malignant glioma	4.44e-06	2.92e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—malignant glioma	4.42e-06	2.91e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—malignant glioma	4.32e-06	2.84e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—malignant glioma	4.31e-06	2.83e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—malignant glioma	4.16e-06	2.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—malignant glioma	4.14e-06	2.72e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—malignant glioma	4.12e-06	2.71e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—malignant glioma	4.08e-06	2.69e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—malignant glioma	4.03e-06	2.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—malignant glioma	4e-06	2.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—malignant glioma	3.81e-06	2.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—malignant glioma	3.75e-06	2.47e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—malignant glioma	3.69e-06	2.43e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—malignant glioma	3.63e-06	2.39e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—malignant glioma	3.5e-06	2.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—malignant glioma	3.38e-06	2.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—malignant glioma	3.07e-06	2.02e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—malignant glioma	3.02e-06	1.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—malignant glioma	2.93e-06	1.93e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—malignant glioma	2.86e-06	1.88e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—malignant glioma	2.4e-06	1.58e-05	CbGpPWpGaD
